Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Cash & Equivalents (2020 - 2025)

BioAtla (BCAB) has disclosed Cash & Equivalents for 6 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • For Q4 2025, Cash & Equivalents fell 91.23% year-over-year to $4.3 million; the TTM value through Dec 2025 reached $4.3 million, down 91.23%, while the annual FY2025 figure was $4.3 million, 91.23% down from the prior year.
  • Cash & Equivalents hit $4.3 million in Q4 2025 for BioAtla, down from $8.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $269.9 million in Q3 2021 and bottomed at $100000.0 in Q3 2023.
  • Average Cash & Equivalents over 5 years is $124.1 million, with a median of $124.7 million recorded in 2023.
  • Year-over-year, Cash & Equivalents soared 112730.98% in 2021 and then plummeted 99.94% in 2023.
  • BioAtla's Cash & Equivalents stood at $245.0 million in 2021, then dropped by 12.03% to $215.5 million in 2022, then crashed by 76.61% to $50.4 million in 2023, then decreased by 2.69% to $49.0 million in 2024, then tumbled by 91.23% to $4.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $4.3 million, $8.3 million, and $18.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.